Avalon GloboCare Launches “BrAce for Impact" Affiliate Marketing Program for the KetoAir Breathalyzer Device
Avalon GloboCare (NASDAQ: ALBT) has launched the 'BrAce for Impact' affiliate marketing program for KetoAir™, an AI-enabled breathalyzer device for ketogenic health monitoring. The program, developed following demand from recent health conferences, offers affiliates discount codes and commissions on sales.
The initiative provides marketing materials and brand resources to affiliates, targeting metabolic coaches, podcasters, health authors, and influencers. KetoAir™, FDA-registered (No. 3026284320), measures breath acetone concentration using nano-sensor technology to assess ketosis status, with companion apps available on both Apple and Google platforms.
Avalon GloboCare (NASDAQ: ALBT) ha lanciato il programma di marketing affiliato 'BrAce for Impact' per KetoAir™, un dispositivo di analisi del respiro abilitato dall'IA per il monitoraggio della salute chetogenica. Questo programma, sviluppato in seguito alla richiesta proveniente da recenti conferenze sanitarie, offre agli affiliati codici sconto e commissioni sulle vendite.
L'iniziativa fornisce materiali di marketing e risorse per il brand agli affiliati, concentrandosi su allenatori metabolici, podcaster, autori di salute e influencer. KetoAir™, registrato presso la FDA (No. 3026284320), misura la concentrazione di acetone nel respiro utilizzando la tecnologia dei nano-sensori per valutare lo stato di chetosi, con app companion disponibili su entrambe le piattaforme Apple e Google.
Avalon GloboCare (NASDAQ: ALBT) ha lanzado el programa de marketing de afiliados 'BrAce for Impact' para KetoAir™, un dispositivo de alcotest habilitado por IA para el monitoreo de la salud cetogénica. Este programa, desarrollado tras la demanda de conferencias de salud recientes, ofrece a los afiliados códigos de descuento y comisiones sobre las ventas.
La iniciativa proporciona materiales de marketing y recursos de marca a los afiliados, dirigidos a entrenadores metabólicos, podcasters, autores de salud e influencers. KetoAir™, registrado en la FDA (No. 3026284320), mide la concentración de acetona en el aliento utilizando tecnología de nano-sensores para evaluar el estado de cetosis, con aplicaciones complementarias disponibles en ambas plataformas de Apple y Google.
Avalon GloboCare (NASDAQ: ALBT)이 케토겐 건강 관리를 위한 AI 지원 호흡 측정 장치인 KetoAir™에 대한 'BrAce for Impact' 제휴 마케팅 프로그램을 출시했습니다. 최근 건강 회의에서의 요청에 따라 개발된 이 프로그램은 제휴사에 대한 할인 코드와 판매에 대한 커미션을 제공합니다.
이 이니셔티브는 대사 코치, 팟캐스터, 건강 저자 및 인플루언서를 대상으로 제휴사에게 마케팅 자료 및 브랜드 리소스를 제공합니다. KetoAir™는 FDA 등록 제품(등록번호: 3026284320)으로, 나노 센서 기술을 활용하여 호흡 중 아세톤 농도를 측정하고 케토시스 상태를 평가하며, Apple과 Google 플랫폼 모두에서 사용할 수 있는 동반 앱을 제공합니다.
Avalon GloboCare (NASDAQ: ALBT) a lancé le programme de marketing d'affiliation 'BrAce for Impact' pour KetoAir™, un dispositif d'analyse de souffle habilité par IA pour le suivi de la santé cétogène. Ce programme, développé en réponse à la demande lors de récentes conférences sur la santé, offre aux affiliés des codes de réduction et des commissions sur les ventes.
L'initiative fournit des matériaux marketing et des ressources de marque aux affiliés, ciblant les coachs métaboliques, les podcasters, les auteurs de santé et les influenceurs. KetoAir™, enregistré auprès de la FDA (No. 3026284320), mesure la concentration d'acétone dans l'haleine en utilisant la technologie des nano-capteurs pour évaluer l'état de cétonie, avec des applications disponibles sur les plateformes Apple et Google.
Avalon GloboCare (NASDAQ: ALBT) hat das Affiliate-Marketing-Programm 'BrAce for Impact' für KetoAir™ gestartet, ein KI-fähiges Atemanalysegerät zur Überwachung der ketogenen Gesundheit. Das Programm, das auf Nachfrage von jüngsten Gesundheitskonferenzen entwickelt wurde, bietet Affiliates Rabattcodes und Provisionen auf Verkäufe.
Die Initiative stellt Affiliate-Marketing-Materialien und Markenressourcen zur Verfügung, die sich an Stoffwechselcoaches, Podcaster, Gesundheitsautoren und Influencer richten. KetoAir™, FDA-zugelassen (Nr. 3026284320), misst die Acetonkonzentration im Atem mithilfe von Nano-Sensortechnologie zur Beurteilung des Ketose-Status, mit begleitenden Apps, die sowohl auf Apple- als auch auf Google-Plattformen verfügbar sind.
- Launch of new affiliate marketing program creating additional sales channels
- FDA-registered device with established market presence
- Cross-platform availability (iOS and Android) expanding market reach
- None.
Insights
The launch of KetoAir's affiliate marketing program represents a minimal impact on Avalon GloboCare's immediate financial prospects. While the program could potentially expand the device's market reach, several factors limit its significance:
- The ketogenic diet market, though growing, remains a niche segment
- Affiliate marketing programs typically take 6-12 months to show meaningful revenue impact
- The program's success heavily depends on influencer adoption and end-user conversion rates
The company's
FREEHOLD, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced the launch of the "BrAce for Impact" affiliate marketing program for KetoAir™, a handheld breathalyzer device equipped with AI-enabled software and Hot App shareable technology, specifically designed for ketogenic health monitoring.
The “BrAce for Impact” affiliate marketing program was developed in response to demand from attendees at the Hack Your Health Conference (Austin, May 31-June 2, 2024) and the Keto Pa-LOU-za Conference (Louisville, KY, Oct. 11-13, 2024). The program offers an attractive discount and commission structure, enabling affiliates to provide a coupon code and earn commissions on each sale. This structure encourages KetoAir™ promotion through social media, helping spread awareness among a wide audience.
"We’re excited to launch the ‘BrAce for Impact’ program to empower influencers, health coaches, and content creators to share KetoAir™ and The Case for BrAce with their audiences,” said David Jin, M.D., Ph.D., CEO of Avalon GloboCare. “This program not only supports affiliates with marketing materials but also fosters authentic engagement as participants document their personal health journeys using KetoAir™. We look forward to building a vibrant community committed to ketogenic health.”
Affiliates in the program will receive support in the form of professionally designed graphics and marketing materials, along with access to KetoAir's brand tags and logos for authentic health journey updates. This initiative targets metabolic coaches, podcasters, health authors, experts, disease management and reversal companies, and other influencers.
Joining the “BrAce for Impact” program is simple: affiliates complete a quick form, and an affiliate marketing agreement is automatically sent to them for signature. Interested individuals can join the program through this link.
To purchase your own KetoAir device, visit www.ketoair.us.
KetoAir™ is a handheld breathalyzer, specifically engineered for ketogenic health management (United States FDA registration number: 3026284320). KetoAir™ measures an individual's breath acetone concentration (BrAce), a ketone body that rises as fat oxidation increases. By leveraging the nano-sensor-based technology, the KetoAir™ breathalyzer is designed to assess the ketosis status of its individual user and is accessible on both the Apple App Store and Google Play Store.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. Avalon is working to establish a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results. The Company also provides laboratory services, offering a broad portfolio of diagnostic tests, including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates, however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of KetoAir and the product’s ability to compete with other testing methods for determining ketosis. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Form 8-Ks filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
FAQ
What is the BrAce for Impact program launched by Avalon GloboCare (ALBT)?
What is the FDA registration number for Avalon's (ALBT) KetoAir device?